FindTrial
Sign In

The Prognostic Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Therapy: A Multicenter Model Based on the log odds of positive lymph nodes

The Prognostic Risk Stratification of Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Therapy: A Multicenter Model Based on the log odds of positive lymph nodes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108342
Enrollment
Unknown
Registered
2025-08-28
Start date
2025-08-30
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

LODDS1 group: LODDS value less than -1.16:None
LODDS2 group: LODDS value greater than or equal to -1.16 and less than -0.56:None
LODDS3 group: LODDS value greater than or equal to -0.56:None

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Non-small cell lung cancer (including lung adenocarcinoma or lung squamous cell carcinoma) confirmed by pathology; 2. Neoadjuvant chemotherapy or neoadjuvant chemotherapy combined with immunotherapy, followed by radical surgery; 3. Have complete clinical and pathological data, including the number of positive lymph nodes and the total number of resected lymph nodes.

Exclusion criteria

Exclusion criteria: 1. Previous or concurrent history of other malignant tumors; 2. No radical resection or systematic lymph node dissection was performed; 3. The postoperative survival time was less than 1 month.

Design outcomes

Primary

MeasureTime frame
Overall Survival, OS;Disease-Free Survival, DFS;—

Countries

China

Contacts

Public ContactShuchen Chen

Fujian Medical University Union Hospital

cscdoctor@163.com+86 139 5020 7801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026